Delving into the Latest Updates on Hoshi University with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

CKAP2 x GNA11 x GNAQ x NOSs	1

关联

2

项与 Hoshi University 相关的药物

FR900359

靶点

CKAP2 x GNA11 x GNAQ x NOSs

作用机制

CKAP2 modulators [+3]

在研机构

中国科学院合肥物质科学研究院 [+3]

原研机构

Hoshi University

在研适应症

胃癌 [+2]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

SJL-01

靶点-

作用机制-

在研机构-

原研机构

Hoshi University

在研适应症-

非在研适应症

内脏利什曼病

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

14

项与 Hoshi University 相关的临床试验

JPRN-UMIN000054928

/ Completed临床2期IIT

Verification of the Anxiety-Reducing Effect of Bergamot Essential Oil on Aromastone before Exams: A Parallel Group Comparative Study - Verification of the Anxiety-Reducing Effect of Bergamot Essential Oil on Aromastone before Exams: A Parallel Group Comparative Study

开始日期2024-07-12

申办/合作机构

Hoshi University

JPRN-UMIN000053519

/ CompletedN/AIIT

A Clinical Trial on the Alleviation of Psychological Stress Through the Use of Lavender Essential Oil Before Sleep and Upon Waking: A Crossover Trial - A Clinical Trial on the Alleviation of Psychological Stress Through the Use of Lavender Essential Oil Before Sleep and Upon Waking: A Crossover Trial

开始日期2024-02-03

申办/合作机构

Hoshi University

JPRN-UMIN000053518

/ CompletedN/AIIT

A Clinical Trial on the Alleviation of Psychological Stress Through the Use of Chamomile Essential Oil Before Sleep and Upon Waking: A Crossover Trial - A Clinical Trial on the Alleviation of Psychological Stress Through the Use of Chamomile Essential Oil Before Sleep and Upon Waking: A Crossover Trial

开始日期2024-02-03

申办/合作机构

Hoshi University

100 项与 Hoshi University 相关的临床结果

登录后查看更多信息

0 项与 Hoshi University 相关的专利（医药）

登录后查看更多信息

5,433

项与 Hoshi University 相关的文献（医药）

2025-06-01·Patient Education and Counseling

Readability of written information for patients across 30 years: A systematic review of systematic reviews

Review

作者: Yokota, Rie ; Okuhara, Tsuyoshi ; Furukawa, Emi ; Kiuchi, Takahiro ; Okada, Hiroko

OBJECTIVEThis study conducted a systematic review of the systematic reviews of readability assessment studies to contribute to future readability research and practice by providing a comprehensive overview of information readability for patients.METHODSWe searched multiple databases. We included systematic reviews of studies that quantitatively assessed the readability of health information.RESULTSThis study included 24 systematic reviews, which assessed the readability of 29,424 materials across 438 studies from 1990 to 2022. All systematic reviews reported that the readability of most materials exceeded the recommended sixth to eight-grade reading level. The readability level did not improve between 2001 and 2022, when the included systematic reviews were published.CONCLUSIONSWe found that the required reading level of information was too high for patients in all clinical areas included in this systematic review. We also identified gaps in readability assessment research in clinical areas and across media types and languages, which should be addressed by future studies.PRACTICE IMPLICATIONSHealth professionals should use available guidelines to make existing patient information easy to read and to write easy-to-read patient information, thereby improving readability. Such efforts are needed regardless of the organizations these professionals work at.

2025-05-01·Journal of Hazardous Materials Advances

Uncovering new psychoactive substances research trends using large language model-assisted text mining (LATeM)

作者: Akiyama, Hiroshi ; Ito, Rie ; Kodama, Kota ; Kobayashi, Yoshiyuki ; Kageyama, Itsuki ; Uchida, Takumi ; Iwasaki, Yusuke ; Tsuda, Kazuhiko

The emergence of new psychoactive substances (NPS) has become a significant public health concern over the past few decades.This study employed text-mining techniques and large language models (LLMs) to examine NPS research trends from 1990 to 2024.Over 12,000 publications from the Web of Science database were analyzed using the proposed Large Language-assisted Text Mining (LATeM) method to identify key patterns and shifts in research focus.The results indicated an evolution in NPS research from basic pharmacol. studies in the 1990s to more diverse approaches encompassing public health, policies, and advanced anal. methods in recent years.The opioid crisis, particularly the emergence of fentanyl, has significantly influenced research priorities since 2020.A notable increase in NPS-related publications was observed, growing from 105 in the 1990s to over 6000 in the 2020s.Furthermore, the research focus shifted from traditional drugs to synthetic cannabinoids and stimulants in the 2000s and 2010s, and subsequently to opioids in the 2020s.Emerging areas of study include forensic applications, environmental impacts, and advanced anal. techniques.This study demonstrates the efficacy of integrating LLMs with text mining to identify emerging trends in NPS research.Our findings underscore the need for continued interdisciplinary collaboration and the development of novel strategies to address the evolving NPS challenges.Future research should prioritize enhancing early detection methods, investigating the long-term health consequences of NPS use, and developing effective prevention and treatment programs.

2025-04-25·Cancer Research

Abstract LB310: Methylation synthetic lethality: SMARCA1 methylation and inhibition of pyrimidine synthesis

作者: Mashiko, Ryoma ; Ohashi, Yui ; Takeshima, Hideyuki ; Ushijima, Toshikazu

AbstractSynthetic lethality is a promising therapeutic strategy, but the number of combinations of a mutated gene and a therapeutic target gene is limited. In contrast with a mutation, DNA methylation is frequently present in many types of cancers, and can be a rich source for a synthetic lethality. So far, BRCA1 methylation with a PARP inhibitor is known as a synthetic lethality [Kawachi et al., Breast Cancer Res Treat, 181:323-329, 2020]. We have been searching to identify a novel synthetic lethal combinations by using methylated genes. In this study, as a methylated gene, we focused on SMARCA1, which was often methylated in various types of cancers [Takeshima et al., Cancer Lett, 357:328-338, 2015], and encodes a ISWI-type chromatin remodeling factor. Genes lethal for cancer cell lines with SMARCA1 low expression were screened for using the sgRNA screening database [DepMap], and two of top 3 candidate genes identified were genes related to pyrimidine biosynthesis pathway, DHODH and UMPS. To experimentally validate the usefulness of this combination, five SMARCA1-methylated and seven -unmethylated cell lines were treated with a DHODH inhibitor, and SMARCA1-methylated cell lines showed higher sensitivity. These cell lines included three cell lines not used in the screening, validating the usefulness of the combination. Sensitivity to DHODH inhibition in SMARCA1-methylated cell line, RKO, was reduced by exogenous overexpression of SMARCA1, indicating the causal role of SMARCA1 methylation for the synthetic lethality. We are now evaluating in vivo usefulness of this combination. These results showed that DNA methylation is a rich source for a synthetic lethality, and the inhibition of pyrimidine synthesis is a promising therapeutic strategy for SMARCA1-methylated cancers.Citation Format:Hideyuki Takeshima, Yui Ohashi, Ryoma Mashiko, Toshikazu Ushijima. Methylation synthetic lethality: SMARCA1 methylation and inhibition of pyrimidine synthesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB310.

100 项与 Hoshi University 相关的药物交易

登录后查看更多信息

100 项与 Hoshi University 相关的转化医学

登录后查看更多信息